241 related articles for article (PubMed ID: 30990000)
1. Treatment of venous thromboembolism with tinzaparin in oncological patients.
Ageno W; Barni S; Di Nisio M; Falanga A; Imberti D; Labianca RF; Mantovani L
Minerva Med; 2019 Jun; 110(3):251-258. PubMed ID: 30990000
[TBL] [Abstract][Full Text] [Related]
2. CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients.
Lee AY; Bauersachs R; Janas MS; Jarner MF; Kamphuisen PW; Meyer G; Khorana AA;
BMC Cancer; 2013 Jun; 13():284. PubMed ID: 23764005
[TBL] [Abstract][Full Text] [Related]
3. Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial.
Lee AYY; Kamphuisen PW; Meyer G; Bauersachs R; Janas MS; Jarner MF; Khorana AA;
JAMA; 2015 Aug; 314(7):677-686. PubMed ID: 26284719
[TBL] [Abstract][Full Text] [Related]
4. Tinzaparin for Long-Term Treatment of Venous Thromboembolism in Patients With Cancer: A Systematic Review and Meta-Analysis.
Martínez-Zapata MJ; Mathioudakis AG; Mousa SA; Bauersachs R
Clin Appl Thromb Hemost; 2018 Mar; 24(2):226-234. PubMed ID: 28288527
[TBL] [Abstract][Full Text] [Related]
5. Tinzaparin-a review of its molecular profile, pharmacology, special properties, and clinical uses.
Amerali M; Politou M
Eur J Clin Pharmacol; 2022 Oct; 78(10):1555-1565. PubMed ID: 35871241
[TBL] [Abstract][Full Text] [Related]
6. Long-term treatment of venous thromboembolism with tinzaparin compared to vitamin K antagonists: a meta-analysis of 5 randomized trials in non-cancer and cancer patients.
Laporte S; Bertoletti L; Romera A; Mismetti P; Pérez de Llano LA; Meyer G
Thromb Res; 2012 Dec; 130(6):853-8. PubMed ID: 22939430
[TBL] [Abstract][Full Text] [Related]
7. Anticoagulant use in patients with cancer associated venous thromboembolism: a retrospective cohort study.
Rahme E; Feugère G; Sirois C; Weicker S; Ramos E
Thromb Res; 2013 Mar; 131(3):210-7. PubMed ID: 23290095
[TBL] [Abstract][Full Text] [Related]
8. Thrombosis, cancer and renal insufficiency: low molecular weight heparin at the crossroads.
Scotté F; Rey JB; Launay-Vacher V
Support Care Cancer; 2012 Dec; 20(12):3033-42. PubMed ID: 22960941
[TBL] [Abstract][Full Text] [Related]
9. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer.
Akl EA; Rohilla S; Barba M; Sperati F; Terrenato I; Muti P; Schünemann HJ
Cochrane Database Syst Rev; 2008 Jan; (1):CD006649. PubMed ID: 18254108
[TBL] [Abstract][Full Text] [Related]
10. Venous thromboembolism prevention with LMWHs in medical and orthopedic surgery patients.
Deitelzweig SB; Vanscoy GJ; Niccolai CS; Rihn TL
Ann Pharmacother; 2003 Mar; 37(3):402-11. PubMed ID: 12639173
[TBL] [Abstract][Full Text] [Related]
11. The Treatment of Venous Thromboembolism in Patients with Cancer.
Prandoni P
Adv Exp Med Biol; 2017; 906():123-135. PubMed ID: 27620308
[TBL] [Abstract][Full Text] [Related]
12. Tinzaparin for venous thromboembolism in patients with renal impairment: a single-centre, prospective pilot study.
Yeung J; Dix CHK; Ritchie AG; Kow M; Chen VMY
Intern Med J; 2023 Jan; 53(1):68-73. PubMed ID: 32786035
[TBL] [Abstract][Full Text] [Related]
13. Community-based treatment of venous thromboembolism with a low-molecular-weight heparin and warfarin.
Hyers TM; Spyropoulos AC;
J Thromb Thrombolysis; 2007 Dec; 24(3):225-32. PubMed ID: 17334932
[TBL] [Abstract][Full Text] [Related]
14. Low-Molecular-Weight Heparin in Cancer Patients: Overview and Indications.
Voigtlaender M; Langer F
Hamostaseologie; 2019 Feb; 39(1):67-75. PubMed ID: 30703821
[TBL] [Abstract][Full Text] [Related]
15. Low-molecular-weight heparins for the prevention and treatment of venous thromboembolism.
Ornstein DL; Hong-Dice YG; Papini JR
Mil Med; 2001 Jul; 166(7):593-601. PubMed ID: 11469031
[TBL] [Abstract][Full Text] [Related]
16. The treatment of venous thromboembolism in patients with cancer.
Prandoni P
Intern Emerg Med; 2010 Oct; 5 Suppl 1():S27-30. PubMed ID: 20865471
[TBL] [Abstract][Full Text] [Related]
17. Weight-adjusted tinzaparin for venous thromboembolism prophylaxis in bariatric surgery patients weighing 160 kg or more.
Li A; Eshaghpour A; Tseng EK; Douketis JD; Anvari M; Tiboni M; Siegal DM; Ikesaka RT; Crowther MA
Thromb Res; 2021 Feb; 198():1-6. PubMed ID: 33246191
[TBL] [Abstract][Full Text] [Related]
18. Selecting an anticoagulant for recurrent venous thromboembolism in cancer.
Goodin S
Am J Health Syst Pharm; 2005 Nov; 62(22 Suppl 5):S10-3. PubMed ID: 16286363
[TBL] [Abstract][Full Text] [Related]
19. The low molecular weight heparin, tinzaparin, in thrombosis and beyond.
Mousa SA
Cardiovasc Drug Rev; 2002; 20(3):199-216. PubMed ID: 12397367
[TBL] [Abstract][Full Text] [Related]
20. Tinzaparin in outpatients with pulmonary embolism or deep vein thrombosis.
Dager WE; King JH; Branch JM; Chow SL; Ferrer RE; Pak S; Togioka PY; White RH
Ann Pharmacother; 2005; 39(7-8):1182-7. PubMed ID: 15956232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
